Presentation is loading. Please wait.

Presentation is loading. Please wait.

Treatment Outcomes in Stage I Lung Cancer

Published byPhoebe Horn Modified over 5 years ago

Similar presentations

Presentation on theme: "Treatment Outcomes in Stage I Lung Cancer"— Presentation transcript:

1 Treatment Outcomes in Stage I Lung Cancer
Varun Puri, MD, MSCI, Traves D. Crabtree, MD, Jennifer M. Bell, BSN, Stephen R Broderick, MD, Daniel Morgensztern, MD, Graham A. Colditz, MD, DrPH, Daniel Kreisel, MD, PhD, A. Sasha Krupnick, MD, G. Alexander Patterson, MD, Bryan F. Meyers, MD, MPH, Aalok Patel, BS, Clifford G. Robinson, MD  Journal of Thoracic Oncology  Volume 10, Issue 12, Pages (December 2015) DOI: /JTO Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

2 Figure 1 Consort diagram showing schema of study subject selection and analysis. Journal of Thoracic Oncology  , DOI: ( /JTO ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

3 Figure 2 A, Kaplan–Meier survival of patients undergoing surgery versus SBRT. This is an unmatched comparison (A) and propensity score matched comparison (B). Kaplan–Meier survival of patients undergoing sublobar resection (wedge or segmentectomy) versus SBRT. This is an unmatched comparison (C) and propensity score matched comparison (D). Journal of Thoracic Oncology  , DOI: ( /JTO ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Treatment Outcomes in Stage I Lung Cancer"

Similar presentations

Su K. Metcalfe, MD, MPH, Michael T

Su K. Metcalfe, MD, MPH, Michael T
Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.
Stephen R. Broderick, MD, MPHS 

Stephen R. Broderick, MD, MPHS 
Perioperative versus Preoperative Chemotherapy with Surgery in Patients with Resectable Squamous Cell Carcinoma of Esophagus  Yang Zhao, MD, ZhiJun Dai,

Perioperative versus Preoperative Chemotherapy with Surgery in Patients with Resectable Squamous Cell Carcinoma of Esophagus  Yang Zhao, MD, ZhiJun Dai,
Michael Y. Chang, MD, MPH, Steven J. Mentzer, MD, Yolonda L

Michael Y. Chang, MD, MPH, Steven J. Mentzer, MD, Yolonda L
Melanie Subramanian, MD, Timothy McMurry, PhD, Bryan F

Melanie Subramanian, MD, Timothy McMurry, PhD, Bryan F
Evaluation of the Reliability of Clinical Staging of T2 N0 Esophageal Cancer: A Review of The Society of Thoracic Surgeons Database  Traves D. Crabtree,

Evaluation of the Reliability of Clinical Staging of T2 N0 Esophageal Cancer: A Review of The Society of Thoracic Surgeons Database  Traves D. Crabtree,
One in every 14 patients with early-stage lung cancer is not being treated!  Benny Weksler, MD, MBA  The Journal of Thoracic and Cardiovascular Surgery 

One in every 14 patients with early-stage lung cancer is not being treated!  Benny Weksler, MD, MBA  The Journal of Thoracic and Cardiovascular Surgery 
Survival after Sublobar Resection for Early-Stage Lung Cancer: Methodological Obstacles in Comparing the Efficacy to Lobectomy  Emanuela Taioli, MD, PhD,

Survival after Sublobar Resection for Early-Stage Lung Cancer: Methodological Obstacles in Comparing the Efficacy to Lobectomy  Emanuela Taioli, MD, PhD,
Endoscopic Ultrasound for Early Stage Esophageal Adenocarcinoma: Implications for Staging and Survival  Traves D. Crabtree, MD, Wael N. Yacoub, MD, Varun.

Endoscopic Ultrasound for Early Stage Esophageal Adenocarcinoma: Implications for Staging and Survival  Traves D. Crabtree, MD, Wael N. Yacoub, MD, Varun.
ALK FISH and IHC: You Cannot Have One without the Other

ALK FISH and IHC: You Cannot Have One without the Other
Does the method of radiologic surveillance affect survival after resection of stage I non– small cell lung cancer?  Traves D. Crabtree, MD, Varun Puri,

Does the method of radiologic surveillance affect survival after resection of stage I non– small cell lung cancer?  Traves D. Crabtree, MD, Varun Puri,
Paul J. Scheel, BS, Traves D. Crabtree, MD, Jennifer M

Paul J. Scheel, BS, Traves D. Crabtree, MD, Jennifer M
Adjuvant Chemotherapy for Patients with T2N0M0 NSCLC

Adjuvant Chemotherapy for Patients with T2N0M0 NSCLC
Matthew J. Boyer, MD, PhD, Christina D. Williams, PhD, MPH, David H

Matthew J. Boyer, MD, PhD, Christina D. Williams, PhD, MPH, David H
Clinical T2N0 Esophageal Cancer: Identifying Pretreatment Characteristics Associated With Pathologic Upstaging and the Potential Role for Induction Therapy 

Clinical T2N0 Esophageal Cancer: Identifying Pretreatment Characteristics Associated With Pathologic Upstaging and the Potential Role for Induction Therapy 
Electronic Updates for JTO Readers

Electronic Updates for JTO Readers
Treatment and Prognosis of Isolated Local Relapse after Stereotactic Body Radiotherapy for Clinical Stage I Non-Small-Cell Lung Cancer  Masatsugu Hamaji,

Treatment and Prognosis of Isolated Local Relapse after Stereotactic Body Radiotherapy for Clinical Stage I Non-Small-Cell Lung Cancer  Masatsugu Hamaji,
Joshua E. Rosen, BASc, Michelle C

Joshua E. Rosen, BASc, Michelle C
National Patterns of Care and Outcomes After Combined Modality Therapy for Stage IIIA Non–Small-Cell Lung Cancer  Aalok P. Patel, BS, Traves D. Crabtree,

National Patterns of Care and Outcomes After Combined Modality Therapy for Stage IIIA Non–Small-Cell Lung Cancer  Aalok P. Patel, BS, Traves D. Crabtree,

Similar presentations

Ads by Google